Search
Treosulfan
go.drugbank.com/drugs/DB11678ApprovedInvestigational[L52245] It was approved by the EMA in June 2019[L16965] and by the FDA in January 2025 for use in combination with [fludarabine].[L52575] … Treosulfan is a prodrug alternative to [busulfan] for myeloablative conditioning prior to hematopoietic stem cell transplantation.
Synonyms: L-threitol-1,4-dimethanesulfonateDelandistrogene moxeparvovec
go.drugbank.com/drugs/DB16802ApprovedInvestigational[L47026] DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading to a deficiency in functional dystrophin protein. … of a muscle-specific promoter (MHCK7) to enhance expression in cardiac and skeletal muscles.
Inosine
go.drugbank.com/drugs/DB04335ApprovedIt is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules. … A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose.
Synonyms: INOBaclofen
go.drugbank.com/drugs/DB00181ApprovedInvestigational[A245338] Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FDA in 1977. … Baclofen is a gamma-aminobutyric acid (GABA) agonist used as a skeletal muscle relaxant.
Products: BACLOFEN AL 25MG TABLETTENTrilaciclib
go.drugbank.com/drugs/DB15442ApprovedInvestigationalTrilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing … [L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016.
Metrizoic acid
go.drugbank.com/drugs/DB09346ApprovedMetrizoic acid is a molecule used as a contrast medium. It present a higher risk of allergic reactions due to its high osmolality. Its approval has been discontinued by the FDA. … In general, the drug was well tolerated by patients during cardiac examinations [A32091].
Categories: Compounds used in a research, industrial, or household settingPolatuzumab vedotin
go.drugbank.com/drugs/DB12240ApprovedInvestigationalPolatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. … [L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved by Health Canada on July 9, 2020.[L44141]
Abaloparatide
go.drugbank.com/drugs/DB05084ApprovedInvestigational[L740] It is a synthetic 34 amino acid peptide with 41% homology to human parathyroid hormone 1-34 and human PTHrP 1-34. … [L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis.
Clofazimine
go.drugbank.com/drugs/DB00845ApprovedInvestigationalWithdrawnIt was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. … Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy.
Vernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalIntravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA. … It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates.